Portelius, Erik http://orcid.org/0000-0003-2708-7372
Olsson, Bob
Höglund, Kina
Cullen, Nicholas C.
Kvartsberg, Hlin
Andreasson, Ulf
Zetterberg, Henrik
Sandelius, Åsa
Shaw, Leslie M.
Lee, Virginia M. Y.
Irwin, David J.
Grossman, Murray
Weintraub, Daniel
Chen-Plotkin, Alice
Wolk, David A.
McCluskey, Leo
Elman, Lauren
McBride, Jennifer
Toledo, Jon B.
Trojanowski, John Q.
Blennow, Kaj
Funding for this research was provided by:
National Institutes of Health (P30 AG-10124-27, P01 AG-17586-18, P50 NS-053488-11)
Torsten Söderbergs Stiftelse
Hjärnfonden
Knut och Alice Wallenbergs Stiftelse
Stiftelsen för Gamla Tjänarinnor
Article History
Received: 13 December 2017
Revised: 19 April 2018
Accepted: 21 April 2018
First Online: 26 April 2018
Compliance with ethical standards
:
: EP, LMS, NCC, ACP, DW, ÅS, UA, KH, HK, DJI, LE, LM, BO, JBT, and MG declare that they have no conflict of interest. DAW received grant funding from Merck, Biogen, Avid Radiopharmaceuticals and Eli Lilly and personal fees from GE Healthcare, Merck, and Janssen. HZ is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg, has served at advisory boards of Eli Lilly and Roche Diagnostics and has received travel support from TEVA. KB has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.